Rintala 2007.

Methods	Randomised, double‐blind, placebo‐controlled, 3‐way cross‐over, not enriched. No imputation method mentioned Titration over 4 weeks to pain control, limit of tolerability, or maximum amitriptyline 150 mg daily, gabapentin 3600 mg daily, then stable dose for remainder of 8‐week period; 1‐week washout then cross‐over Analysis for completers only
Participants	SCI at any level and degree of completeness. Pain duration before treatment > 6 months, PI at randomisation > 5/10 N = 38, only 22 participants completed all 3 cross‐overs Mean age 43 years, 9% women Initial pain intensity 5.6/10
Interventions	Amitriptyline 150 mg daily (max) Gabapentin 3600 mg daily (max) Placebo (diphenhydramine) 75 mg daily Oxycodone + paracetamol 5/325 mg (max 8 tablets daily) allowed for rescue medication
Outcomes	No dichotomous data for efficacy or harm Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5 Department of Veterans Affairs grant
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"table of random numbers"
Allocation concealment (selection bias)	Low risk	Prepared, packaged and labelled by remote, commercial compounding pharmacy
Blinding (performance bias and detection bias) All outcomes	Low risk	"identical capsules"
Incomplete outcome data (attrition bias) Efficacy	High risk	Completers only
Size Efficacy	High risk	< 50 participants per treatment arm (38 randomised, 22 completed 3 phases)